Benefits
Diuretic activity (traditional use and animal studies only)
Traditional Ayurvedic use as a diuretic (mutrala) for over 2,000 years. Rat studies report increased urine output, and reviews compare that effect to thiazide-type diuretics, but that comparison comes from animals, not from people. No human trial of punarnava as a diuretic is cited on this page, and none of the three cited studies was done in humans. Whether it changes fluid balance in people is unknown.
Liver-protective effects in rats and mice (no human data)
Multiple animal studies show Boerhavia diffusa extracts reduce liver enzyme elevation (ALT, AST, ALP) and bilirubin in rodents deliberately given liver toxins such as acetaminophen (paracetamol) and carbon tetrachloride. Mechanism involves antioxidant defense (SOD, catalase, GSH support), reduced lipid peroxidation, and direct membrane stabilization. None of this has been shown in people. The only liver study cited on this page was done in Swiss albino mice given paracetamol. Liver disease is a serious medical condition that needs a doctor, and punarnava should not be used to treat it.
Nephroprotective in animal models of kidney injury
All of this work is in cells and animals. The kidney study cited here gave rats the antibiotic gentamicin to damage their kidneys, then found that Boerhavia diffusa root extract lowered blood urea nitrogen, creatinine and oxidative stress markers. Other reports use kidney cells in a dish or rodents given cisplatin or paracetamol. One 90 day comparison was run in dogs with chronic renal failure, which is veterinary rather than human evidence. Nothing has been shown in people, and kidney disease needs a doctor rather than a supplement.
Anti-inflammatory and antioxidant activity in laboratory and animal studies
Boeravinones, eupalitin, and other Boerhavia phytochemicals demonstrate NF-κB inhibition, COX-2 reduction, and direct radical scavenging in vitro and animal models. May contribute to broader rejuvenative claims (rasayana classification in Ayurveda). No human trial of punarnava for inflammation is cited on this page, and no cited study measured an inflammation marker in a person, so whether any of this happens in people is unknown.
Mechanism of action
Diuretic activity via uncertain target
Rat studies report increased urine output. This has never been measured in people. Mechanism not fully characterized — possibly involves Na+/K+ pump modulation, increased renal blood flow, or direct tubular effects. Distinct from typical thiazide or loop diuretic mechanisms (lacks specific transporter inhibition). The rotenoids and punarnavoside may contribute. In animals the effect looks milder and slower in onset than a prescription diuretic, and the two have never been compared in humans.
Antioxidant protection of renal/hepatic tissue
Extracts upregulate endogenous antioxidants (SOD, catalase, GPx, GSH) and reduce lipid peroxidation (MDA) in rats and mice given toxins that damage the kidney or liver. Eupalitin and other flavonoids contribute to direct scavenging. Combined with metal chelation effects, provides protection against drug-induced nephrotoxicity (cisplatin) in rodent models.
Anti-fibrinolytic and tissue-stabilizing
Punarnavoside is a plant compound that slows clot breakdown in laboratory tests. It has been proposed to stabilize tissue and reduce fluid leaking out of blood vessels, which is one idea for how the herb might reduce swelling, but this is a laboratory hypothesis rather than something measured in people. Mechanism distinct from diuretic activity; complementary contribution to traditional 'shothahara' (edema-reducing) classification.
Calcium channel modulation (preclinical)
Some boeravinones and Boerhavia extracts block calcium channels in test tube studies. In theory that could matter for blood vessels and smooth muscle, but it has not been shown in animals or people and its significance is unknown.
Clinical trials
Comprehensive review (Mishra S, Aeri V, Gaur PK, Jachak SM 2014, Biomed Res Int 2014:808302, doi:10.1155/2014/808302).
Ethnopharmacology, phytochemistry, and pharmacology review of Boerhavia diffusa across Indian medicinal systems and Western pharmacological literature.
Documented extensive preclinical evidence for: diuretic activity (rat models, comparable to thiazide diuretics), hepatoprotection (multiple toxin models), antidiabetic effects, anti-inflammatory action, immunomodulation. Noted limitation: relatively few rigorous human clinical trials despite extensive ethnobotanical use. The authors concluded that modern clinical trials are needed before any of this can be applied to patients, and that gap still exists. This paper reviews existing animal and laboratory work; it contains no new data and no human results.
Animal study (Olaleye MT, Akinmoladun AC, Ogunboye AA, Akindahunsi AA 2010, Food Chem Toxicol 48(8-9):2200-2205, doi:10.1016/j.fct.2010.05.047).
Rats with acetaminophen-induced liver damage. Aqueous and ethanolic Boerhavia diffusa leaf extracts evaluated for antioxidant and hepatoprotective properties.
Pretreatment with B. diffusa extracts significantly decreased elevated alkaline phosphatase, lactate dehydrogenase, ALT, AST, and bilirubin levels in serum. Liver enzyme elevations also ameliorated. Protected against acetaminophen-induced lipid peroxidation. Concluded hepatoprotective property mediated through augmentation of antioxidant defenses. Animal evidence; not directly translatable to human clinical efficacy.
Comparative clinical evaluation (Naik AB, Devarakonda R, Nagayya N et al. 2015, Vet World).
CRF dogs (Spitz, German Shepherd, Labrador, etc., 8-12 years) randomized to Boerhavia root hydroalcoholic extract (Himalaya Punarnava — 250 mg per capsule) or enalapril 5 mg. 90-day comparative outcome assessment.
Outcomes with B. diffusa root extract treatment were comparable to enalapril for canine CRF. Advantages: faster improvement in Hb, potassium, phosphorus by day 30, urinary protein by day 90. Mortality: 5 dogs in enalapril group vs 2 in punarnava group died between 60-90 days. This was a small veterinary trial in dogs with no placebo group, comparing the herb against a drug rather than against no treatment. It says nothing about what punarnava does in people, and no human trial has been run.